PAUL TIEN: Open Payments
NPI 1134792070 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$349 in 13 payments from 7 companies in 2025. Trend: 2023 $246 · 2024 $343 · 2025 $349
Food & beverage: $250Education: $99
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $138 |
| Sumitomo Pharma America, Inc. | 3 | $67 |
| Dendreon Pharmaceuticals LLC | 2 | $57 |
| TOLMAR, INC. | 2 | $29 |
| PFIZER INC. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Innovation Technologies Inc | 1 | $15 |
Products named: PROVENGE, GEMTESA, Xtandi, JATENZO, PADCEV, ORGOVYX, Trelstar, IRRISEPT.
Industry payments across TX — which companies pay providers there.
